The four questions that split these hip pathways

Many patients arrive at this decision with a straightforward question: do I need an injection, or do I need an operation? In practice, the answer depends not on a preference for one over the other but on four clinical facts about the hip that can be established through imaging and examination.

Is the damage focal or spread across the whole joint? A contained patch of cartilage loss behaves very differently from the diffuse thinning seen in established osteoarthritis, and the treatments suited to one are largely unsuitable for the other.

Is there bone damage underneath the cartilage? Cartilage repair procedures work on the cartilage layer itself; when the bone beneath has also deteriorated, the repair needs to address both layers.

What does the X-ray show about the degree of joint-space narrowing? The Tönnis grading system classifies this narrowing. Once Tönnis grade reaches 2 or above — indicating established osteoarthritis across the joint — cartilage preservation and repair procedures including AMIC, OATS, OCA, and surgical ChondroFiller implantation are considered unlikely to succeed, and the treatment conversation shifts toward joint replacement.

What is the patient's age and activity demand? Younger, more active patients with large lesions involving bone loss may tolerate a more complex reconstruction that would be disproportionate for an older patient with lower functional targets.

These four questions are the actual branching points in the pathway. Which one applies to a particular hip — not a general preference for injection over surgery — is what determines the right direction of travel.

ChondroFiller injection: the outpatient collagen scaffold route

ChondroFiller injection delivers an acellular Type I collagen gel into the hip joint through an ultrasound-guided needle, in an outpatient clinic under local anaesthesia — no theatre visit, no incision, no general anaesthetic. Once placed, the gel self-sets within approximately three to five minutes, forming a viscoelastic scaffold that lines the worn joint surface and recruits the patient's own progenitor cells through a process described as matrix-induced chondrogenesis. The device is CE-marked as a Class III medical device, manufactured by Meidrix Biomedicals in Germany.

The mechanism is additive rather than restorative: instead of targeting a single focal repair site, the injected collagen cushions the joint surface from above. This makes it suited to a different patient profile than the surgical techniques described in adjacent sections. The relevant clinical window is diffuse, mild-to-moderate cartilage wear — where the joint lining has thinned broadly but established joint-space narrowing has not yet taken hold. Once Tönnis grade reaches 2 or above, published evidence suggests the collagen scaffold cannot overcome the mechanical environment of a significantly degenerated joint, and the injection is unlikely to be appropriate.

Outcome data for the collagen gel in the hip include a published cohort in which 17 of 21 patients with acetabular cartilage lesions above 2 cm² achieved good or excellent results at three to five years, with that series reporting modified Harris Hip Score gains of approximately 30 points. Those patients received ChondroFiller delivered arthroscopically in a research setting — an earlier route described in the peer-reviewed literature. Critically, patients in that same cohort with pre-existing Tönnis Grade 2–3 osteoarthritis had poor results, reinforcing that careful patient selection against OA grade is as important as the procedure itself. The current pathway at Lincolnshire Hip applies the same collagen scaffold technology through an image-guided outpatient needle rather than an arthroscope.

Ultrasound guidance at the hip is not a preference but a technical requirement. The anterior recess of the hip joint sits up to seven centimetres below the skin surface, with the femoral nerve, artery, and circumflex vessels running directly alongside the needle path. Accuracy under continuous ultrasound imaging is 90–96%, compared with 70–80% for landmark-guided injection — an odds ratio of 5.18. Real-time imaging throughout the procedure is standard practice, not an optional enhancement.

AMIC: the surgical standard for focal hip cartilage defects

For patients whose hip imaging shows a focal, full-thickness cartilage defect without established joint-space narrowing, AMIC (autologous matrix-induced chondrogenesis) is the most extensively studied surgical repair option available for the hip. A single operating-theatre visit covers both stages of the repair: the surgeon first creates small channels through the bone beneath the defect — a technique called microfracture — to allow marrow-derived stem cells to migrate into the lesion, then immediately secures a bi-layer collagen membrane over the site to stabilise those cells and guide the healing response. No donor tissue is needed, and no second operation follows.

The evidence base for this approach is substantial. A 2025 systematic review and meta-analysis drawing on 628 hips across 12 published studies reported a pooled success rate of 99.6%, with a mean improvement in the modified Harris Hip Score of 35.8 points. Patients in these studies averaged 35.8 years of age with lesions of approximately 3.3 cm². Conversion to total hip arthroplasty was near zero in appropriately selected cases — a marked contrast with microfracture-alone cohorts, where THA conversion rates of up to 32.6% have been reported in comparable series.

AMIC is indicated for Grade III–IV focal chondral defects measuring ≥2 cm² in patients with Tönnis grade 0–1. Tönnis grade ≥2 is a contraindication: once established joint-space narrowing is present across the joint, marrow stimulation combined with a scaffold cannot reverse the underlying degeneration.

Two further points shape outcomes. Compared with two-stage procedures such as ACI or MACI — which require a separate biopsy, laboratory cell culture, and a return to theatre — AMIC is more cost-effective and logistically straightforward without sacrificing clinical results. And preclinical evidence from a rabbit hip model suggests that preserving the labrum and joint capsule during surgery significantly improves the quality of cartilage healing, which is why contemporary AMIC technique places considerable emphasis on protecting these structures.

OATS: autograft transfer for small bone-involving hip defects

When the damage extends below the cartilage surface into the bone underneath, surface-only repair is insufficient. AMIC addresses the cartilage layer; OATS (osteochondral autograft transfer) addresses both layers together by moving a cylindrical plug of the patient's own bone and cartilage — harvested from a less mechanically loaded part of the same hip — directly into the defect. The transplanted plug restores the full structural column: the subchondral bone foundation and the hyaline cartilage cap above it.

The principal constraint is donor-site availability. In published multicenter data, femoral head autograft defects averaged roughly 1.6×1.0 cm — approximately the diameter of a small coin. Because the harvest site must itself remain mechanically sound, there is a firm upper limit on how much tissue can be safely transferred. OATS is therefore not a viable option when the defect is larger than this; for those cases, the pathway moves to osteochondral allograft transplantation (OCA), discussed in the next section.

Within its correct indication — a small, bone-involving defect in a hip with low-grade OA — the durability evidence is encouraging. In a multicenter cohort with a mean follow-up of 9.5 years, patients who had received autograft transfer achieved a mean modified Harris Hip Score of 87.6, and none of the remaining patients had required conversion to total hip arthroplasty. That longevity compares favourably with cartilage-only repair in lesions where the bone has been compromised.

Donor-site morbidity — the potential for discomfort or functional change at the harvest site — is a real consideration that warrants a frank preoperative conversation with the surgeon, even though published series report it as an acceptable trade-off for appropriately selected patients.

OCA: fresh allograft for large or complex hip defects in younger patients

Larger defects — or those where no usable autograft tissue exists — bring a third surgical option into consideration. Osteochondral allograft transplantation (OCA) transplants donor-derived cartilage and bone into the defect site, removing the donor-availability ceiling that restricts OATS. In the hip, the target is almost always the femoral head, and accessing it requires surgical hip dislocation: a more demanding procedure than AMIC or OATS, with a correspondingly longer and more complex recovery.

The published hip cohorts are drawn from a young patient group — mean ages of 21 to 22 years — which reflects the clinical reality that OCA tends to be considered when other joint-preserving options have been exhausted or are not applicable. Outcomes in the short to medium term are meaningful: in one series of 24 patients with femoral head defects averaging 488 mm², the modified Harris Hip Score improved from 62.1 to 83.9 and the iHOT-12 score from 35.5 to 77.5 at minimum two-year follow-up. However, 25% of patients in that cohort required conversion to total hip arthroplasty at a mean of 3.8 years post-operatively. A separate multicenter study of 19 OCA patients reported a comparable 21.1% THA conversion rate. These figures are worth stating plainly: for the right patient, OCA can preserve the joint and restore meaningful function for several years, but it is more accurately described as a joint-preserving bridge than a definitive long-term solution.

One modifiable factor has a striking influence on whether the graft survives. The method used to preserve the donor tissue before implantation matters considerably. In a 33-patient hip preservation series, grafts stored using the MOPS (Missouri Osteochondral Preservation System) protocol achieved 100% success at one year, against 50% with standard preservation methods — an odds ratio of 47. Patients considering OCA are advised to ask their surgeon specifically which preservation protocol will be used.

The evidence base for OCA in the hip remains less extensive than for AMIC. Long-term hip-specific follow-up data are limited, and no direct head-to-head trials comparing OCA with AMIC or OATS in the hip have been published. Decisions in this area therefore rest on available cohort data, lesion characteristics, and an honest assessment of what joint preservation can realistically achieve for an individual patient.

Matching the right hip pathway to you

Putting the four pathways together, the decision branches from two questions: how widespread is the damage, and is the bone involved?

Diffuse OA with Tönnis grade 2 or above closes the surgical repair options entirely. At that stage, AMIC, OATS, and OCA are all contraindicated — the joint environment cannot support focal rebuilding — and the ChondroFiller outpatient injection pathway becomes the appropriate cartilage-level option, delivering a collagen scaffold under real-time ultrasound guidance without requiring a theatre visit.

Where imaging shows a focal defect with the joint still largely intact (Tönnis 0–1), the next branch point is bone involvement. A full-thickness cartilage lesion of 2 cm² or above with intact subchondral bone points toward AMIC, the most thoroughly evidenced single-stage surgical option currently available for the hip. Where the bone beneath is also compromised but the defect is small, OATS transfers the patient's own bone-and-cartilage plug, with durable outcomes at nearly a decade of follow-up in selected cases. When the defect exceeds what autograft can fill, OCA extends the joint-preserving option further — at the cost of greater surgical complexity and a meaningfully higher rate of eventual hip replacement.

Age and activity level refine the choice within each branch. A 28-year-old and a 55-year-old with the same 4 cm² bone-involving lesion may reasonably reach different conclusions when weighing longevity, recovery demand, and the realistic trajectory toward joint replacement.

No direct head-to-head trials comparing these four approaches in the hip have been published, which means clinical judgement, thorough imaging, and an honest individual assessment remain essential at every branch point — not as a limitation of the evidence, but as the standard of careful hip care.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients for hip assessment without referral, with clinics in Sleaford and Grantham.

1. [1] Arthroscopic treatment of chondral defects in the hip: AMIC, MACI, microfragmented adipose tissue transplantation (MATT) and other options. (2017). https://doi.org/10.1051/sicotj/2017029 https://doi.org/10.1051/sicotj/2017029
2. [2] Trends in Cartilage Repair Techniques for Chondral Defects in the Hip in Germany: An Epidemiological Analysis from 2006 to 2022. (2024). https://doi.org/10.3390/life14101262 https://doi.org/10.3390/life14101262
3. [3] Hip articular cartilage repair with autologous mesenchymal stem cells (MSCs): 4-year results in prospective controlled study. (2025). https://doi.org/10.1093/jhps/hnaf011.025 https://doi.org/10.1093/jhps/hnaf011.025
4. [4] Osteochondral Allograft Transplantation of the Femoral Head via Surgical Hip Dislocation: Survivorship and PROMs at Minimum 2-Year Follow-Up. (2025). https://doi.org/10.1177/23259671251385115 https://doi.org/10.1177/23259671251385115
5. [5] Preserving Hip Stability Yields Better Cartilage Repair With Microfracture Treatment: A Rabbit Study. (2025). https://doi.org/10.1016/j.asmr.2025.101284 https://doi.org/10.1016/j.asmr.2025.101284
6. [6] Outcomes of autologous chondrocyte transplantation (ACT) and autologous matrix-induced chondrogenesis (AMIC) in the hip: a systematic review and meta-analysis. (2025). https://doi.org/10.1186/s13018-025-05862-5 https://doi.org/10.1186/s13018-025-05862-5
7. [7] Outcomes associated with hip preservation using osteochondral allograft transplants and acetabular labrum reconstruction. (2024). https://doi.org/10.1177/11207000241288445 https://doi.org/10.1177/11207000241288445
8. [8] Osteochondral Allograft and Autograft Transplant for Femoral Head Defects: A Multicenter Study. (2025). https://doi.org/10.1177/03635465251338062 https://doi.org/10.1177/03635465251338062